1520 related articles for article (PubMed ID: 24461133)
1. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
2. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
[TBL] [Abstract][Full Text] [Related]
3. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
[TBL] [Abstract][Full Text] [Related]
4. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
[TBL] [Abstract][Full Text] [Related]
6. Outpatient single-session yttrium-90 glass microsphere radioembolization.
Gates VL; Marshall KG; Salzig K; Williams M; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2014 Feb; 25(2):266-70. PubMed ID: 24332243
[TBL] [Abstract][Full Text] [Related]
7. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
[TBL] [Abstract][Full Text] [Related]
9. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
[TBL] [Abstract][Full Text] [Related]
10. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
[TBL] [Abstract][Full Text] [Related]
11. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
12. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
[TBL] [Abstract][Full Text] [Related]
13. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
[TBL] [Abstract][Full Text] [Related]
15. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting.
Gaba RC; Zivin SP; Dikopf MS; Parvinian A; Casadaban LC; Lu Y; Bui JT
Radiology; 2014 May; 271(2):602-12. PubMed ID: 24533871
[TBL] [Abstract][Full Text] [Related]
17. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.
Iñarrairaegui M; Thurston KG; Bilbao JI; D'Avola D; Rodriguez M; Arbizu J; Martinez-Cuesta A; Sangro B
J Vasc Interv Radiol; 2010 Aug; 21(8):1205-12. PubMed ID: 20598574
[TBL] [Abstract][Full Text] [Related]
18. Measurement of the Tumor-to-Normal Ratio for Radioembolization of Hepatocellular Carcinoma: A Prospective Study Comparing 2-Dimensional Perfusion Angiography, Technetium-99m Macroaggregated Albumin, and Yttrium-90 SPECT/CT.
Brunson CP; McGregor HJ; Hennemeyer CT; Patel MV; Woodhead GJ; Young SJ
J Vasc Interv Radiol; 2024 Jan; 35(1):94-101. PubMed ID: 37783268
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
